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Abstract
Background: Ischemic stroke is a major cause of permanent disability and inflammation has a prominent role in stroke pathology.
Stem cell therapy is a new approach for stroke treatment. Mesenchymal stem cells (MSCs) are appropriate for this approach due to
neuroprotective and immunomodulatory effects.
Objectives: In this experimental study, the neuroprotective effects of mesenchymal stem cells (MSCs) on brain injury after transient
middle cerebral artery occlusion (tMCAO) in rats was investigated with emphasis on inflammatory factors.
Methods: Mesenchymal Stem Cells were isolated from bone marrow of rats and expanded by cell culture. Thirty-six male Wistar rats
were randomly selected and divided to 6 groups. The MCAO model was performed in 4 groups with 24 and 72 hours of reperfusion.
A single infusion of 2× 106 MSCs was transplanted in one of the 24-hour and 72-hour groups and others received saline. In the sham
groups, surgery was done without MCAO. Behavioral tests were evaluated and infarct volume was measured by staining of brain
sections. Serum levels of Interleukin (IL) 1β and Tumor necrosis factor (TNF)αwere measured by the enzyme linked immunosorbent
assay (ELISA). Relative expression of Interleukin (IL)1β, tumor necrotizing factor (TNF)α, and IL6 genes were assessed in penumbra
of the ischemic region using real time polymerase chain reaction (PCR).
Results: The study results indicated that total behavioral scores were increased 72 hours after MSC transplantation (14.5± 2.0, P <
0.01). Moreover, MSCs decreased the infarct volume both 24 hours (18.82± 1.58, P < 0.01) and 72 hours (14.4± 1.53, P < 0.05) after
MCAO. Serum levels of IL-1β and TNFαwere increased after MCAO, yet MSCs transplantation decreased IL-1β (368.3± 109.5, P < 0.001)
and TNFα (126.9± 38.6, P < 0.01) compared to saline. Also, relative gene expression of IL1β, TNFα, and IL6 was decreased by MSCs
transplantation (P < 0.05).
Conclusions: The MSCs had a neuroprotective effect in ischemic stroke via modulation of inflammatory response, and serum levels
of IL1β and TNFα could be used as markers for evaluating anti-inflammatory effects of MSCs.
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1. Background
Ischemic stroke is known as a major cause of mortality
and continual disability worldwide. Despite the advance-
ment in biology and pathology of stroke, effective treat-
ment is not available. Ischemic stroke is characterized by
cerebral artery blockage and abrupt restriction of blood
supply to an area of the brain tissue (1). Lack of oxygen
and glucose in the core of ischemic region leads to neural
cells necrosis, while surrounding cells are compromised.
Any treatment that can save these cells is effective in reduc-
ing the infarct zone and complications of ischemic stroke.
Transient ischemia and subsequent reperfusion trigger ox-
idative damage, excitotoxicity, and inflammatory response
(2). The entrance of cerebral resident macrophage, mi-
croglia (3, 4), and dendritic cells (5) in to injured brain
tissue, and the release of cytokines, chemokines and in-
filtration of peripheral blood monocyte, granulocyte and
lymphocytes (6) exacerbated the inflammation and sub-
sequent expansion of ischemic lesions (7). It has been re-
ported that suppression of inflammation in the early stage
of ischemic stroke could be reduced in the infarct zone and
neural injures (8). Therefore, stem cell therapy seems to
be a new horizon in ischemic stroke recovery. This study
examined the blood levels of inflammatory factors after
brain ischemia and MSCs transplantation and suggested
these factors as markers of stroke assessment and thera-
peutic procedures.
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Mesenchymal stem cells (MSCs) are multipotent adult
stem cells with neuroprotective effects (9). Although the
exact mechanisms of this protection are unknown, mod-
ulation of inflammatory response (10, 11), decrease of
macrophages and neutrophils infiltration (12), activations
of microglia and macrophages and suppression of T and B
cells maturation (13, 14), has been mention in experimen-
tal studies as probable mechanisms. Moreover, ability of
migration to damaged tissue, release of growth factor and
cytokine and trans-diffrentiation into neurons and glial
cells are some properties that make MSCs a good choice for
cell therapy of ischemic stroke (15). The current study in-
vestigated the effects of bone marrow-derived mesenchy-
mal stem cells on motor and sensory defects recovery, in-
farct size, gene expression of pro-inflammatory cytokines
in brain tissue and serum levels of these cytokines after
MCAO in rat.
2. Methods
This study was performed at the anatomical sciences
research center, Kashan University of Medical Sciences
(KAUMS), Kashan, Iran during year 2016.
2.1. Animals
Male Wistar rats aged 8 to 10 weeks old and weighting
210 to 250 g were prepared at Kashan University of medical
sciences lab animal center. Rats were bred and maintained
in a pathogen-free environment at a temperature of 20 ±
2°C and had free access to food and water under a 12-hour
light/dark cycle throughout the experiment. Animal care
and all of experimental procedures were confirmed by the
ethics committee of KAUMS. The code and date of ethical
approval was 2012.06.01 (p/29/5/1/932).
2.2. Isolation, Expansion and Characterization of Mesenchymal
Stem Cells
Mesenchymal stem cells were derived from bone mar-
row of rats. Once male Wistar rats (4 to 6 week old) were
sacrificed, tibia and femoral bones were removed under
aseptic conditions and bone marrow was flushed out using
a 5-mL syringe and 23-gauge needle with cell culture me-
dia. The cell suspension was centrifuged at 360 g for 5 min-
utes. Sedimentary cells were suspended in high-glucose
DMEM (Invitrogen; USA) that was supplemented with 10%
(v/v) fetal bovine serum (Invitrogen; USA), 100 U/mL peni-
cillin and 100 µg/mL streptomycin (Sigma; Germany), and
seeded in 75 cm2 cell culture flasks (Orange Scientific, Bel-
gium). Flasks were placed in an incubator (Memmert; Ger-
many) with 5% CO2 and 85% humidity at 37°C tempera-
ture. After 24 hours, media and non-attached cells were dis-
carded and replaced with fresh media. Adherent cells were
allowed to expand in the cell culture flask. The medium
was exchanged once every 2 days.
Bone marrow-derived MSCs were identified by po-
tential differentiation to adipocytes and osteocytes.
For demonstrating of this capability, 5000/cm2 cells
were seeded in 6-well plates and adipogenic differenti-
ation medium was added that contained low glucose
DMEM (Invitrogen; USA) supplemented with FBS and
penicillin/streptomycin (same as the growth media),
plus 50 µg/mL of ascorbic acid- 2 phosphate, 100 nM
dexamethasone, and 50 µg/mL indomethacin (all from
Sigma; Germany). The media was exchanged half-and-
half every 2 days. After 21 days, the cells were fixed and
stained by Oil red O (Sigma-Aldrich) and investigated for
fat vacuoles and adipocyte cells. Similarly, osteogenic
differentiation medium consisting of the growth media
plus 10 mM glycerol-2-phosphate, 50 µg/mL ascorbic
acid- 2- phosphate, and 100 nM dexamethasone (all from
Sigma-Aldrich) were added to plated cells. The media was
exchanged half-and-half every 2 days, and cell variation
was evaluated under the microscope. After 21 days, cells
were fixed and stained by Alizarin Red (Sigma-Aldrich)
and checked for osteocyte and calcium sediments in the
cytoplasm and intra cellular matrix.
Bone marrow-derived cells were characterized with
surface CD markers, which were checked by flow cytome-
try. In brief, the cell suspension was washed twice with PBS.
For direct assays, one million cells were incubated with
PE-conjugated anti-CD34 antibody (Abcam, USA), anti-CD45
antibody (Santa Cruz Biotechnology_ USA), anti-CD44 anti-
body (Abcam, USA), anti-CD73 antibody (SH-3) (Cell Signal-
ing Technology, USA), anti-CD90 antibody (Abcam, USA),
and anti-CD105 (SH- 2) antibody (Abcam, USA) at 4°C for
30 minutes, in the dark and then washed twice with PBS.
The cells were analyzed by cytometric analysis using the BD
FACS Calibur flow cytometer (BD Biosciences, USA) and in-
terpreted with Flowjo 7.6.1 software; MSCs in passages 3 to
5 were used for cell therapy.
2.3. Transient Middle Cerebral Artery Occlusion
An experimental model of focal ischemia in the rat was
performed using transient middle cerebral artery occlu-
sion (tMCAO) as previously described with few modifica-
tions (16, 17). In brief, the rats were anesthetized by inhala-
tion of 4% isoflurane (Piramal Critical Care; USA) via a face
mask and maintained under anesthesia with 2% isoflurane
throughout the surgery. Rats were reposed on a warm pad
(Narco Bio System; USA) to maintain their body tempera-
ture at 37 ± 0.5°C during the operation. Cerebral Blood
Flow (CBF) was measured using a Laser-Doppler flowme-
ter (Moor Instruments VMS-LDF2, UK). Probes of the Laser-
Doppler were fixed on the drill-thinned skull, in position,
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4 mm lateral and 2 mm posterior to the bregma, on both
ipsi/contra lateral hemisphere and basic CBF was recorded.
A middle longitudinal incision on the neck was performed
and left common carotid artery (CCA) was exposed. Next,
a commercially available catheter (Doc Cole, USA) was in-
serted in the lumen of the CCA and propelled to the In-
ternal Carotid Artery (ICA), until it reached to a stay or an
abrupt fall in the CBF occurred. At this point, the catheter
occluded the entrance of the MCA, and the catheter was
fixed by a clamp and left to rest for 60 minutes. The CBF was
monitored during the occlusion. Then the catheter was
removed and CCA was ligated permanently. The MCA was
perfused again through the cerebral arterial circle (Wilis
loop), and CBF returned to almost the previous amount.
Three hours after reperfusion, 2× 106 MSCs in 0.5 mL saline
buffer were infused via the tail vein in both the 24-hour
and 72-hour MSC groups, and the rats in the control groups
only received 0.5 mL of saline.
2.4. Behavioral Assessment
Garsia motor and sensory behavioral tests were per-
formed with a few changes as described (18), exerted to as-
sess post-ischemic neurological deficits. The following 6
tests were performed before ischemic stroke and 24 or 72
hours after reperfusion by 2 blinded readers.
Spontaneous activity: Rats were placed in the middle
of a 60 × 90-cm sized cage within an unknown environ-
ment for 3 minutes. Scoring was done as follows 0 = rats
not moving; 1 = rats moved hardly but not rising up in the
cage; 2 = rats moving around in the cage waveringly yet not
approaching the walls, nevertheless ultimately going up in
the cage; 3 = rats moving around, seeking the environment
and approaching three walls of the cage.
Forepaw outstretching: Rats were lifted by the tail and
the synchrony of the left and right forelimbs outstretch-
ing was checked. Scores: 0 = right forelimb entirely con-
stricted, 1 = right side moves faintly; 2 = outstretching on
right side was less than the left side; 3 = equal outstretch-
ing in both forelimbs.
Ability to climb: Rats were placed on a 2-cm step space
stairwell. Normally rats use all four limbs to climb the stair.
Scores: 1 = Rats unable to climb, revolved and oftentimes
plopped. 2 = right side damaged when climbing or not
clutching as tightly as the left side; 3 = rat climbing easily
and clutching the stair tightly.
Body proprioception: each side of the body of rats was
touched with a blunt stick and response to the stimulus
was evaluated, scores: 1 = not responding to goad on the
right side. 2 = slow response to stimulus on the right side,
3 = startled by the goad on both sides equally and turned
its head.
Behavior of walk: spontaneous walking activity was
checked. Scores: 0 = not walking, 1 = walks while wob-
bling; 2 = walks with shift to the right; 3 = walks rectilin-
early ahead.
Head proprioception: sensory function was evaluated
by brushing the vibrissae and checking the response on the
left and right sides. Scores: 1 = no response to stimulus on
the right side. 2 = Slow reaction to the stimulus on the right
side; 3 = Turns its head to the stimulus side.
Finally, the scores of all these tests were summed,
which resulted in a minimum score of 3 and a maximum
score of 18 points overall.
2.5. Infarct Volume (TTC)
At the end of the ischemia/reperfusion (I/R) period (24
hours or 72 hours), rats were anesthetized by injection
of chloral hydrate (350 mg/kg) and blood sampling was
performed. Then, the rats were sacrificed, their brains
were removed carefully and excised into 2-mm coronal sec-
tions. The brain slices were immersed in 2% (w/v) 2,3,5-
triphenyltetrazolium chloride (TTC) dissolved in normal
saline solution at 37 ºC for 5 to 10 minutes. The mitochon-
drial enzyme in living cells reduced TTC to insoluble triph-
enylformazan crystals that stained normal brain tissue to
red, but infarcted area and necrotic cells remained white.
Photographs of the brain slices were evaluated by Optika
Vision Pro software and infarct size was measured.
2.6. Real Time PCR
Gene expression of inflammatory factors, including In-
terleukin (IL)-1β, IL-6 and Tumor Necrotizing Factor-alpha
(TNFα), were evaluated in the cortical cerebral tissue sur-
rounding the ischemic lesion (penumbra) using real time
polymerase chain reaction (PCR). The tissue samples were
obtained from penumbra and frozen in liquid nitrogen
quickly, and kept at -80°C until analysis. Total RNA was ex-
tracted from tissue by the RNA extraction kit (Peq gold; Ger-
many). Then cDNA was synthesized from total RNA by Ac-
cuPower® RT-PCR PreMix (Bioneer; Korea). Real time PCR
was performed by RealHelix™ qRT-PCR kit (Nano Helix; Ko-
rea).
Real time PCR reactions were performed in 8 × 6 (0.2
mL) strip (Applied Biosystem, USA) containing 5µL of mas-
ter mix (Nano Helix; Korea), 0.5 µL of both forward and re-
verse primer, 2 µL of diluted cDNA, and 2 µL water. Gene
expression was measured using the Real time PCR technol-
ogy (Applied Biosystem Step One Plus, USA) and a standard-
ized protocol, as described previously (19). The primer se-
quences and annealing temperatures are given in Table 1.
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Table 1. Primer Sequences and Annealing Temperatures (AT) in Real-Time PCR
Gene Primer Sequence AT, °C Size, bp
IL-1β
F CTGTGACTCGTGGGATGATG
58 209
R GGGATTTTGTCGTTGCTTGT
IL-6
F CAAAAGAGAGCCTGGGACTG
58 209
R CAGAATTGCCATTGCACAAC
TNFα
F CTCCCAGAAAAGCAAGCAAC
60 210
R CGAGCAGGAATGAGAAGAGG
HPRT
F GCTGGTGAAAAGGACCTCT
60 284
R CACAGGACTAGAACACCTGC
2.7. Enzyme Linked Immunosorbent Assay
Serum levels of inflammatory factors, interleukin (IL)-
1β and Tumor Necrotizing Factor alpha (TNFα), were mea-
sured by Rat IL1β ELISA Kit and Rat TNFα ELISA Kit (Boster,
USA) as described by the manufacturer’s instructions.
Blood samples were collected from heart of deeply anaes-
thetized rats at the end of reperfusion time and the serum
was stored at -20°C before the analysis.
2.8. Statistical Analysis
Statistical differences between means of values were
compared with One-Way Analysis Of Variance (ANOVA) test,
followed by Tukey’s post hoc test. Ordinal data of behav-
ioral test were analyzed by the Kruskal-Wallis test. All data
had a normal distribution. The normality of data was
checked by the Kolmogrov-Smirnov test. All of statistical
analyses were performed using SPSS software (version 22,
Chicago, IL USA). Results with P value < 0.05 were consid-
ered as significant differences.
3. Results
3.1. Mesenchymal Stem Cells Characterization
Mesenchymal stem cells were characterized using
three properties, including adherence to plastic, ability to
differentiate to adipocytes and osteoblasts, and surface CD
markers. Adherence to plastic was substantially used for
separating MSCs. Bone marrow cells in the first passage are
heterogeneous but after three passages, plastic adherent
spindle-shape like cells spread in flasks (Figure 1A and B).
Capability of differentiation to adipocyte and osteoblast
cells was demonstrated by culturing of these cells in spe-
cial differentiation media. Bone marrow-isolated cells
were differentiated to osteoblast (Figure 1C) and adipocyte
(Figure 1D) after 3 weeks. The purity of these MSCs was as-
sessed by characterization of surface CD marker analysis
using flowcytometry, as previously described (20, 21). The
presence of CD44 (98.3%), CD73 (75.4%), CD90 (99.5%), and
CD105 (99.8%) and absence of hematopoietic markers, such
as CD34 (4.52%) and CD45 (0.3%), in the surface of MSCs were
demonstrated by this flowcytometry technique (Figure 1E).
3.2. Infarct Volume
The span of infarct lesions was indicated by staining
of the brain section with 2,3,5-Triphenyltetrazolium Chlo-
ride (TTC). The size of the infarct area (white zone) and the
total surface of the brain section were measured on slices,
imaged by the Optika Vision Pro software and the ratio (×
100) was calculated and reported as percentage of infarct
volume. Results indicated that infarct volume in the 24-
hour MSC group (18.82± 1.58) was significantly lower than
the 24-hour control (saline) group (27.4 ± 5.67; P < 0.01).
Also, infarct volume in the 72-hour MSC group (14.4± 1.53)
was significantly lower than in the 72-hour saline group
(20.1± 2.77; P < 0.05) (Figure 2).
3.3. Behavioral Assessment
Garcia motor and sensory exams were performed in all
groups, and total scores (max = 18) were compared. Results
indicated that the total score of the Garcia behavioral test
decreased in both the 24-hour (9.5±2.3) and 72-hour (8.5±
3.2) saline groups in comparison to sham groups (17± 0.9;
P < 0.001). Also, it demonstrated a significant increase in
total scores of behavioral tests in the 72-hour MSC groups
(14.5± 2.0; P < 0.01), yet not in the 24-hour MSC groups (13
± 3.4) in comparison with the saline groups.
3.4. Enzyme Linked Immunosorbent Assay
Serum levels of IL-1β and TNFαwere measured by ELISA
method and the results indicated that serum level of IL-
1β, 24 hours (1134± 241.3) and 72 hours (925± 196.8) after
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Figure 1. Mesenchymal Stem Cells Were Isolated From Bone Marrow and Characterized by Morphology, Differentiation Ability and Surface CD Markers
A, in first passage bone marrow derived cells are heterogeneous; B, after three passage MSCs (spindle form cells) were expanded. C, capability of differentiation to adipocyte;
and D, osteoblast in specific media were checked. E, surface CD markers detected by flowcytometry; CD44, CD73, CD90, CD105 were present but CD34 and CD45 were absent.
I/R in the saline group was higher than the sham group af-
ter 24 hours (299.4 ± 79.3) and 72 hours (284 ± 107.5), re-
spectively. However, serum levels of IL-1β in the MSC group
were decreased in 24 hours (851.2 ± 134.3; P < 0.05) and
72 hours (368.3 ± 109.5; P < 0.001) in comparison to the
saline group (Figure 3A). The assessment of TNFα serum
levels in the 24-hour saline group (162.9± 31) and 72-hour
saline group (202.6± 52) showed an increase towards the
sham group (54.3 ± 11.3). However, TNFα serum levels in
the 24-hour MSC group (133± 34.4) had not decreased sig-
nificantly, while serum levels of TNFα in the 72-hour MSC
group (126.9± 38.6) reduced in comparison with the saline
group, significantly (P < 0.01).
3.5. Real time Polymerase Chain Reaction
Inflammatory factor gene expression results were ana-
lyzed by the delta CT method (22), to determine the propor-
tion of target gene delta CT to reference gene delta CT. The
hypoxanthine-guanine phosphoribosyl transferase (HPRT)
was used as a reference gene. Analysis of relative gene ex-
pression in each group was performed using the REST soft-
ware (23). Results showed that the relative gene expres-
sion of IL-1β, IL-6, and TNFα which detected in both the
24-hour and 72-hour saline groups was significantly higher
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Figure 2. The Garcia Motor and Sensory Tests Were Applied for Indicating Neurological Deficit
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Scores of six parameters were compared and total scores (max = 18) were compared in all groups. Total scores in the saline groups 24 hours and 72 hours after tMCAO sig-
nificantly decreased in the sham group (P < 0.001). No significant difference was found between saline and MSC groups 24 hours after reperfusion. However, after 72 hours,
behavioral scores in the MSC group was increased significantly in comparison with the saline group (P < 0.01).
than sham group (P < 0.01). Moreover, relative gene expres-
sion of IL-1β in both the 24-hour (P < 0.01) and 72-hour (P <
0.05) MSC groups was significantly decreased in compar-
ison to the 24-hour and 72-hour saline groups. Also, rel-
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Figure 3. Infarct Volume Was Detected by TTC Staining of Brain Section and Compared Between the Saline and MSC Groups, and the Sham Group
Infarct volume in the 24-hour MSC group was detected significantly higher than the saline group (P < 0.01) and in the 72-hour MSC group was measured higher than the saline
group, significantly (P < 0.05).
ative gene expression of IL-6 in the MSC 24-hour and 72-
hour groups was found to be significantly lower than in the
saline group, respectively (P < 0.05). Again, the TNFα rela-
tive gene expression in the MSC 24-hour groups (but not
72-hour) was observed to be significantly lower than in the
saline group (P < 0.05) (Figures 4 and 5).
4. Discussion
In the present study, neuroprotective effects of MSCs af-
ter ischemic stroke were investigated. The study focused
on anti-inflammatory effects of MSCs and showed that in-
hibition of inflammation is a very important mechanism
of neuroprotection by these cells. The results demon-
strated that intravenous administration of bone marrow-
derived MSCs could be preventing the expansion of infarct
size and improve neurological defects after brain injury
in the rat model of MCAO. This study confirmed recent
experimental evidence indicating that MSCs transplanta-
tion has a therapeutic advantage in cerebral ischemia and
other neurological disorders (24). Although mechanism
of MSC neuroprotection is not fully understood, it is sup-
posed that anti-inflammatory effects of MSCs have an im-
portant role in their neuroprotective properties.
The researchers quantified gene expression of pro-
inflammatory factors in the penumbra region of infarct le-
sion, 24 and 72 hours after MCAO, demonstrating an im-
mense increase in the gene expression of IL-1β, IL-6, and
TNFα. Moreover, the experiment demonstrated that MSCs
transplantation could decrease the expression of these
pro-inflammatory factors in ischemic brain tissue. Im-
munomodulatory properties of MSCs have been demon-
strated in previous studies yet the precise mechanism of
these effects remains unknown (25). These cells could re-
lease various molecules and proteins, which are involved
in the inflammatory response. Most immune cells, in-
cluding neutrophil, monocyte, macrophage dendritic cell,
natural killer cell (NK), T and B lymphocyte, and regula-
tory T cell are impressed by MSCs (26, 27). Immunosup-
pression effects of MSCs could be achieved by cell-cell in-
teraction or the release of several soluble factors, such as
nitric oxide (NO), transform growth factor-β (TGF-β), In-
dole Amine 2,3-Dioxygenase (IDO) hepatocyte growth fac-
tor (HGF), prostaglandin E2 (28), HLA-G (29), CCL-2 (30),
leukemia inhibitory factor (LIF) (31), IL1 receptor antago-
nist (IL1RA) (32), MMP-9 (33), hemeoxygenase-1, galectin-1,
galectin-3, semaphorin-3A, and IL-10 (27, 34).
Several opinions are hypothesized for MSC-mediated
neuroprotection, including release or activation of cy-
tokines and growth factors, angiogenesis, differentiation
of MSCs to neural or glial cells, and replacement of injured
cells (35, 36). Some in vitro experiments demonstrated
the immunosuppressive effects of BM-MSCs on subsiding
lymphocytes alloreactivity in mixed lymphocyte reaction
(MLR) assays (37). Nevertheless, a previous study revealed
that the beneficial effects of MSC transplantation may not
be through direct replacement of differentiated cells (38).
Studies have indicated that MSC therapy decreased
the recruitment of microglia and macrophages to injured
brain tissue and reduced infiltration of peripheral leuko-
cytes to the damaged area (36). These properties maybe of
help to inhibit ischemic lesion extension. Although inva-
sion of immune cells helps in elimination of injured cell
debris, excessive activity of immune cells exacerbated tis-
sue damage. The current results demonstrated that MSCs
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Figure 4. Serum Level of IL-1β Increased After 24 Hours and Remained High Until 72 Hours
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A, MSC transplantation decreased serum level of IL-1β in 24 hours (P < 0.05) and 72 hours (P < 0.001) after MCAO; B, Serum level of TNFα increased after 24 hours and 72 hours.
MSC transplantation decreased the serum level of TNFα, which was significant only after 72 hours (P < 0.01).
Figure 5. Relative Gene Expression of IL-1β, IL- 6, and TNFα Increased After Ischemic Stroke (P < 0.01)
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A, gene expression of IL-1β was decreased by MSC transplantation 24 hours (P < 0.05) and 72 hours (P < 0.01) after MCAO; B, Il-6 gene expression significantly decreased in the
24-hour and 72-hour MSC groups (P < 0.05); C, however, relative gene expression of TNFα in the MSC group 72 hours (but not 24 hours) after reperfusion was significantly
lower than the saline group (P < 0.05).
transplantation decreased infarct volume at both 24 and 72
hours in the MSC group in comparison to the saline group.
These results confirmed previous studies on the neuropro-
tective effects of MSCs in ischemic stroke.
Moreover, this study indicated that gene expression
of pro-inflammatory cytokines, including IL-1β, IL- 6, and
TNFαwere increased in the penumbra of brain ischemic le-
sion. These cytokines were secreted by immune cells, such
as macrophage, microglia, and T cells that were recruited
in the brain after ischemic injury (39). Furthermore, serum
levels of pro-inflammatory cytokines were measured for 24
and 72 hours after ischemia and results indicated an in-
creasing systemic level of IL-1β and TNFα after ischemic
stroke, and MSCs transplantation reduced the serum level
of IL-1β after 24 and 72 hours, while serum level of TNFα
was decreased only 72 hours after MSCs transplantation.
The current study focused on serum levels of cytokines be-
cause of similarity to patient sampling in the clinic. The
researchers disregarded measurement of the IL-6 serum
level, because this cytokine is secreted by MSCs as well as
immune cells (40) and dissociating of its source is impossi-
ble. Moreover, it is suggested that measurement of serum
levels of pro-inflammatory cytokines after stroke could be
of help for recognition of patient status and treatment fol-
low up beside other diagnostic methods, such as magnetic
resonance imaging (MRI), computerized tomography (CT)
scan, and behavioral motor sensory tests.
Also, a decrease in serum levels of pro-inflammatory
cytokines after cell therapy is a good prognosis for post
stroke recovery and displayed a successful treatment.
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Some evidence indicated that MSCs promote the recov-
ery of behavioral test and neurological defects after is-
chemic stroke (41, 42). The results of the present study in-
dicated that motor and sensory neurological defects after
MCAO in rats were improved by MSCs transplantation. Al-
though neurological scores in MSC and saline groups 24
hours after MCAO did not display significant differences,
yet rats in the MSC group, after 72 hours, had better re-
sults in the behavioral exam. It is probable that 24 hours
is too soon for follow up of brain ischemic injury and ther-
apeutic intervention, and delayed post reperfusion alter-
ations caused secondary damage. It is suggested that anti-
inflammatory properties of MSC have an important role
in reducing brain injury and subsequent neurological de-
fects.
The researchers administrated MSCs, 3 hours after
reperfusion for investigation of MSCs effects in the early
stage of acute ischemic stroke. However, several studies
proved the beneficial therapeutic effects of these cells even
several days after the prescription (2, 43).
4.1. Conclusions
In conclusion, anti-inflammatory properties of MSCs
caused a decrease of brain injury and subsequent defects
after MCAO in rat and affected improvement of ischemic
stroke. Moreover, the increased serum levels of IL-β and
TNFα after stroke were decreased by MSCs transplantation.
Therefore, these cytokines could be used as markers for
evaluating the effect of MSCs in improvement of ischemic
stroke.
4.2. Limitations of the Study
This study investigated MCAO and stem cell therapy
after 24 and 72 hours for acute and sub-acute response.
The protective effects of MSc could be investigated in the
chronic phase of stroke until 3 months after MCAO for late
neuronal events, such as delayed neuronal death (DND).
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